These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 16088584)

  • 1. Burkholderia and emerging pathogens in cystic fibrosis.
    LiPuma JJ
    Semin Respir Crit Care Med; 2003 Dec; 24(6):681-92. PubMed ID: 16088584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging and unusual gram-negative infections in cystic fibrosis.
    Davies JC; Rubin BK
    Semin Respir Crit Care Med; 2007 Jun; 28(3):312-21. PubMed ID: 17562501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of Pandoraea species by 16S ribosomal DNA-based PCR assays.
    Coenye T; Liu L; Vandamme P; LiPuma JJ
    J Clin Microbiol; 2001 Dec; 39(12):4452-5. PubMed ID: 11724860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Burkholderia cepacia complex bacteria: opportunistic pathogens with important natural biology.
    Mahenthiralingam E; Baldwin A; Dowson CG
    J Appl Microbiol; 2008 Jun; 104(6):1539-51. PubMed ID: 18217926
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient cohorting and infection control.
    Koch C; Frederiksen B; Høiby N
    Semin Respir Crit Care Med; 2003 Dec; 24(6):703-16. PubMed ID: 16088586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Growth in Stewart's medium is a simple, rapid and inexpensive screening tool for the identification of Burkholderia cepacia complex.
    Vanlaere E; Hansraj F; Vandamme PA; Govan JR
    J Cyst Fibros; 2006 May; 5(2):137-9. PubMed ID: 16386966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The microbiome and emerging pathogens in cystic fibrosis and non-cystic fibrosis bronchiectasis.
    Green H; Jones AM
    Semin Respir Crit Care Med; 2015 Apr; 36(2):225-35. PubMed ID: 25826590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Burkholderia gladioli: five year experience in a cystic fibrosis and lung transplantation center.
    Kennedy MP; Coakley RD; Donaldson SH; Aris RM; Hohneker K; Wedd JP; Knowles MR; Gilligan PH; Yankaskas JR
    J Cyst Fibros; 2007 Jul; 6(4):267-73. PubMed ID: 17137846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective evaluation of emerging bacteria in cystic fibrosis.
    Steinkamp G; Wiedemann B; Rietschel E; Krahl A; Gielen J; Bärmeier H; Ratjen F;
    J Cyst Fibros; 2005 Mar; 4(1):41-8. PubMed ID: 15752680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activities of a novel nanoemulsion against Burkholderia and other multidrug-resistant cystic fibrosis-associated bacterial species.
    LiPuma JJ; Rathinavelu S; Foster BK; Keoleian JC; Makidon PE; Kalikin LM; Baker JR
    Antimicrob Agents Chemother; 2009 Jan; 53(1):249-55. PubMed ID: 18955531
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA microarray-based detection and identification of Burkholderia mallei, Burkholderia pseudomallei and Burkholderia spp.
    Schmoock G; Ehricht R; Melzer F; Rassbach A; Scholz HC; Neubauer H; Sachse K; Mota RA; Saqib M; Elschner M
    Mol Cell Probes; 2009; 23(3-4):178-87. PubMed ID: 19366627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ribosomal DNA-directed PCR for identification of Achromobacter (Alcaligenes) xylosoxidans recovered from sputum samples from cystic fibrosis patients.
    Liu L; Coenye T; Burns JL; Whitby PW; Stull TL; LiPuma JJ
    J Clin Microbiol; 2002 Apr; 40(4):1210-3. PubMed ID: 11923333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RISA-HPLC analysis of lung bacterial colonizers of cystic fibrosis children.
    Nazaret S; Assade F; Brothier E; Freydière AM; Bellon G; Cournoyer B
    J Microbiol Methods; 2009 Jan; 76(1):58-69. PubMed ID: 18929602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival of lung transplant patients with cystic fibrosis harboring panresistant bacteria other than Burkholderia cepacia, compared with patients harboring sensitive bacteria.
    Hadjiliadis D; Steele MP; Chaparro C; Singer LG; Waddell TK; Hutcheon MA; Davis RD; Tullis DE; Palmer SM; Keshavjee S
    J Heart Lung Transplant; 2007 Aug; 26(8):834-8. PubMed ID: 17692788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Burkholderia cepacia complex epidemiology in persons with cystic fibrosis from Australia and New Zealand.
    Kidd TJ; Douglas JM; Bergh HA; Coulter C; Bell SC
    Res Microbiol; 2008 Apr; 159(3):194-9. PubMed ID: 18356026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a novel PCR assay for the identification of the black yeast, Exophiala (Wangiella) dermatitidis from adult patients with cystic fibrosis (CF).
    Nagano Y; Elborn JS; Millar BC; Goldsmith CE; Rendall J; Moore JE
    J Cyst Fibros; 2008 Nov; 7(6):576-80. PubMed ID: 18571996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stenotrophomonas, Achromobacter, and nonmelioid Burkholderia species: antimicrobial resistance and therapeutic strategies.
    Abbott IJ; Peleg AY
    Semin Respir Crit Care Med; 2015 Feb; 36(1):99-110. PubMed ID: 25643274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simultaneous coinfection by multiple strains during Burkholderia cepacia complex infection in cystic fibrosis.
    Yang JH; Spilker T; LiPuma JJ
    Diagn Microbiol Infect Dis; 2006 Feb; 54(2):95-8. PubMed ID: 16406186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bacterial contamination of cystic fibrosis clinics.
    Zuckerman JB; Zuaro DE; Prato BS; Ruoff KL; Sawicki RW; Quinton HB; Saiman L;
    J Cyst Fibros; 2009 May; 8(3):186-92. PubMed ID: 19250885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Burkholderia cepacia complex species: health hazards and biotechnological potential.
    Chiarini L; Bevivino A; Dalmastri C; Tabacchioni S; Visca P
    Trends Microbiol; 2006 Jun; 14(6):277-86. PubMed ID: 16684604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.